Beyond PDL1: OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. "
Press Releases
2023
2022
Date |
Title |
Details |
13 June 2022 |
Oxford BioTherapeutics enters into Commercial License Agreement with Genmab |
View here |
13 June 2022 |
Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates |
View here |
27 May 2022 |
Oxford BioTherapeutics to Present Initial Positive Data from Phase I Trial at ASCO 2022 |
View here |
25 May 2022 |
Oxford BioTherapeutics Announces Collaboration with Agenus to Support the Clinical Development of OBT's Antibody Drug Conjugate OBT076 in Combination with Agenus CPI Balstilimab |
View here |
13 April 2022 |
Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology target |
View here |
07 April 2022 |
AACR 2022: Oxford BioTherapeutics to Present Potential Novel Immuno-Oncology Mechanism in Combination with Checkpoint Inhibitors for Experimental ADC Medicine OBT076 |
View here |
2021
Date |
Title |
Details |
20 Sept 2021 |
Boehringer Ingelheim and Oxford BioTherapeutics Partnership Advances Second Oncology Drug Candidate into the Clinic |
View here |
19 Jan 2021 |
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics' WuXiBody® Platform |
View here |
06 Jan 2021 |
Kite and Oxford BioTherapeutics Establish Cell therapy Research Collaboration in Blood Cancers and Solid Tumours |
View here |
2020
Date |
Title |
Details |
14 Oct 2020 |
Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic |
View here |
09 Jan 2020 |
Oxford BioTherapeutics Initiates Dose-Escalation Portion of U.S. Phase I Clinical Trial for OBT076 in Patients with Advanced Solid Tumors |
View here |
2019
Date |
Title |
Details |
25 Jun 2019 |
Oxford BioTherapeutics Announces Receipt of a Milestone Payment as Boehringer Ingelheim Advances an Oncology Drug Candidate |
View here |
2018
Date |
Title |
Details |
21 Dec 2018 |
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076: An Experimental First in Class ADC Medicine for High Risk Her2 Negative Breast Cancer, Gastric, Lung, Bladder and Ovarian Cancer Patients - US Phase I Clinical Trial to be Initiated |
View here |
11 Dec 2018 |
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million |
View here |
01 Mar 2018 |
Oxford BioTherapeutics Appoints Chief Medical Officer, Abderrahim Fandi |
View here |
2017
Date |
Title |
Details |
13 Jun 2017 |
Oxford BioTherapeutics Appoints Senior Clinical Biotech Executive as Non-Executive Director |
View here |
09 Feb 2017 |
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans |
View here |
26 Jan 2017 |
Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics |
2016
Media
Immunotherapies Expose and Exploit Cancer’s Varied Weaknesses
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.
March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more here about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.